Study wrapper · #764
Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.
Editor's note
This study administers hexarelin as the intervention in a rat model of ischemia-reperfusion acute kidney injury, supported by cell-culture work in human kidney (HK-2) cells. Researchers reported that hexarelin pretreatment was associated with reduced kidney injury and improved function, less tubular damage and lower cell death, via downregulation of pro-apoptotic genes (Caspase-3, Bax, Bad) and upregulation of anti-apoptotic Bcl-2. Molecular docking suggested binding to MDM2, and hexarelin suppressed MDM2 and p53. This is a coherent hexarelin signal combining in-vivo and in-vitro data with a proposed mechanism. Caveats: single-species rodent model, pretreatment design, and mechanistic endpoints. These are preclinical findings; human data would be needed before any clinical conclusion.
Plain-language abstract
This study tested whether the peptide hexarelin could reduce kidney damage caused by a temporary loss and return of blood flow (ischemia-reperfusion), a common problem in surgery and shock. Rats were given hexarelin for seven days before the injury, and separate experiments used human kidney cells deprived of oxygen and then re-oxygenated. Rats that received hexarelin had less kidney damage, better kidney function, and fewer dying kidney cells than untreated rats. Hexarelin lowered the activity of genes that trigger cell death and raised a gene that protects cells. Computer modeling and experiments suggested hexarelin works partly by acting on a protein called MDM2, which in turn regulates the cell-death protein p53. This is an early animal and cell study; the results are promising in rats but do not show what hexarelin does in people.